Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Recruiting 373Active not recruiting 249Completed 145Not yet recruiting 84Terminated 51Suspended 7Withdrawn 6Enrolling by invitation 5Available 4No longer available 3Approved for marketing 3

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6Other hematologic neoplasm 2Lymphoid 1

Conditions

Breast Neoplasms 28Neoplasms 27Prostatic Neoplasms 22Colorectal Neoplasms 16Head and Neck Neoplasms 13Pancreatic Neoplasms 12Brain Neoplasms 11Melanoma 10Neoplasm Metastasis 9Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Leukemia, Myeloid, Acute 7Glioblastoma 7Multiple Myeloma 6Lymphoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Ovarian Neoplasms 5Leukemia 5Hematologic Neoplasms 5Sarcoma 4Lymphoma, B-Cell 4Liver Neoplasms 4Kidney Neoplasms 4

Interventions

fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1belantamab mafodotin 1auricularum 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Dexamethasone 1Cyclophosphamide 1Calcium Dobesilate 1Biopsy 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × 1 year × Clear all
NCT07082270 2026-05-15

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Roswell Park Cancer Institute

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT06698744 2026-05-13

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT05846737 2026-04-29

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT07071909 2026-01-06

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Hematologic Neoplasms

NCT04398680 2025-12-04

DREAMM 13

GlaxoSmithKline

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT02315157 2025-10-15

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Thomas Jefferson University

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡